Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Verici Dx Plc ( (GB:VRCI) ) is now available.
Verici Dx has received Medicare coverage for its Tutivia™ assay, a diagnostic test designed to assess the risk of acute rejection in kidney transplant patients. This coverage, following a positive Technical Assessment by Palmetto GBA, is expected to broaden access to the test, improve patient outcomes, and drive commercial success through increased adoption and revenue recognition. The test, which has already seen a significant increase in order rates, plays a crucial role in enhancing diagnostic accuracy and supporting clinical decision-making in post-transplant care.
More about Verici Dx Plc
Verici Dx plc is a developer of advanced clinical diagnostics focused on organ transplant, particularly kidney transplants. The company offers a suite of cutting-edge tests that utilize artificial intelligence-assisted transcriptomic analysis to provide RNA signatures for assessing immune response and other biological pathways critical for transplant prognosis. Verici Dx aims to enhance patient outcomes through personalized medical management and collaborates with medical device, biopharmaceutical, and data science partners to accelerate innovation.
YTD Price Performance: -64.56%
Average Trading Volume: 1,225,546
Technical Sentiment Signal: Strong Buy
Current Market Cap: £3.33M
For detailed information about VRCI stock, go to TipRanks’ Stock Analysis page.